Unknown

Dataset Information

Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.


ABSTRACT:

Background

Low cellular level of BID is critical for viability of numerous cancer cells. Sensitization of cells to anticancer agents by BID overexpression from adenovirus or pcDNA vectors is a proposed strategy for cancer therapy; however it does not provide any stringent control of cellular level of BID. The aim of this work was to examine whether a fusion of BID with TAT cell penetrating peptide (TAT-BID) may be used for controlled sensitization of cancer cells to anticancer agents acting through death receptors (TRAIL) or DNA damage (camptothecin). Prostate cancer PC3 and LNCaP, non-small human lung cancer A549, and cervix carcinoma HeLa cells were used in the study.

Methods

Uptake of TAT-BID protein by cells was studied by quantitative Western blot analysis of cells extr

SUBMITTER: Orzechowska EJ 

PROVIDER: S-EPMC4210496 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature